Drug profile · INN
decamethonium bromide
SYNCURINE
decamethonium bromide (SYNCURINE) is a muscle-type nicotinic acetylcholine receptor partial agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — decamethonium bromide
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
decamethonium bromide (SYNCURINE) is a muscle-type nicotinic acetylcholine receptor partial agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscle-type nicotinic acetylcholine receptor partial agonist
Primary target: Muscle-type nicotinic acetylcholine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is decamethonium bromide?
decamethonium bromide (SYNCURINE) is a muscle-type nicotinic acetylcholine receptor partial agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for decamethonium bromide?
SYNCURINE is a marketed brand name for decamethonium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of decamethonium bromide?
decamethonium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.